Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exscientia plc

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for Second Quarter and First Half 2024
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at Upcoming Investor Conferences in June
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for First Quarter 2024
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business and Financial Update for the Full Year 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at Upcoming Investor Conferences in March
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for Third Quarter 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Parker Moss to Join Exscientia as EVP, Corporate Development
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Details Pipeline Prioritisation Strategy
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at Upcoming Investor Conferences in September
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for Second Quarter and First Half of 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Business Update for First Quarter 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
From Exscientia plc
Via Business Wire
Tickers EXAI
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
From Exscientia plc
Via Business Wire
Tickers EXAI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.